Latest news with #H.Pylori
Time of India
08-07-2025
- Health
- Time of India
Excessive burping could mean more than a full stomach—here's what your body's trying to tell you
Excessive burping could mean more than a full stomach—here's what your body's trying to tell you Burping or belching, a natural bodily function, releases the audible escape of the buildup of air from our stomach through our mouth. This excessive burping can be an alarming sign of underlying medical conditions or disorders. In order to understand what exactly these medical conditions are, this article explores the information around; what is burping, what causes it, excessive burping- symptoms of medical conditions, difference between occasional burping and frequent burping. Excessive burping is a sign of potential health issues and behavioural disorders. What is burping or belching? Remember getting scolded by your mother at the dinner table for making a sound after a hearty meal? That sound is called Burping. Belching or Burping is a natural process of releasing the air trapped in your stomach through your mouth. In layman's words, when we swallow any kind of food or drink, we end up swallowing air along with it, and this air stretches our stomach until its limit, then a muscle at the lower end of the stomach called the oesophagus relaxes, releasing the trapped air through the mouth. This entire process is called burping or belching, or eructation. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like One plan. Total peace of mind. ICICI Pru Life Insurance Plan Get Quote Undo What causes excessive burping? The very prominent question, 'What causes burping?'- is an answer that is associated with several reasons. These reasons are further categorised into two: 'normal burping' or 'symptom of underlying health condition'. The swallowing of air is the primary cause of excessive burping, which can be done during the following activities: Eat and drink too quickly Talk while eating Drinking Carbonated beverages Wearing ill-fitting dentures Chewing Gum Smoking Excessive burping: Symptom of potential health issues When the burping is frequent and accompanied by other symptoms like abdominal pain, nausea, bloating, weight loss, etc. It is a sign of potential health issues as below: Gastroesophageal Reflux Disease (GERD) When stomach acid flows back up the oesophagus, it leads to gastroesophageal reflux, also known as acid reflux. According to a study published in the National Library of Medicine , excessive belching is considered not just an isolated syndrome but also an associated symptom in patients with gastroesophageal reflux (GERD). Functional Dyspepsia/Chronic Indigestion Functional Dyspepsia or Indigestion is a pattern of symptoms that occur together. It occurs while you are eating and digesting. The isolated symptom of dyspepsia is frequent belching along with discomfort in the upper belly, nausea, and bloating. Helicobacter Pylori Infection Helicobacter Pylori is a bacteria that causes H. Pylori infection, also known as stomach infection. One of the most common symptoms of this infection is frequent belching or burping. Supragastric Belching According to a study published in the National Library of Medicine , Supragastric Belching is a clearly defined pattern found in patients of aerophagia (frequent belching). Meganblase Syndrome Meganblase syndrome is a functional gas bloat syndrome that includes swallowing of large amounts of air while eating or drinking. This air reaches the stomach and creates a large bubble that escapes through burping. This entire process is quite painful for a human body and its symptoms are somewhat similar to heart attack. How to avoid excessive burping It is to be noted that excessive belching can be avoided; however, if it is a symptom of a medical condition, then professional help is needed. The following are lifestyle tips to get rid of excessive burping: Avoid carbonated drinks such as soda, beer and similar others Avoid foods high in carbohydrates- Eat your food and drink slowly Quit smoking Wear fitted dentures Take a short walk or physical exercise after eating Also read | Control high blood pressure using this common kitchen ingredient, says Harvard doctor
Yahoo
02-05-2025
- Business
- Yahoo
Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...
Release Date: May 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Phathom Pharmaceuticals Inc (NASDAQ:PHAT) reported net revenues of $28.5 million for Q1 2025, with a significant increase in filled prescriptions. The company has a strong cash position with $212 million in cash and cash equivalents, aiming to reach profitability by 2026 without additional financing. Phathom Pharmaceuticals Inc (NASDAQ:PHAT) has successfully launched its drug, Vuesna, achieving an annualized run rate of $120 million in net revenues within the first 18 months. The company is implementing cost-saving initiatives to reduce operating expenses to less than $55 million per quarter by Q4 2025. Phathom Pharmaceuticals Inc (NASDAQ:PHAT) has over 120 million lives covered, representing above 80% of the total commercially insured market, and is expanding access through new programs. The company is facing potential supply disruptions for one of its H. Pylori combination packs, although it does not anticipate a material impact on revenues. Phathom Pharmaceuticals Inc (NASDAQ:PHAT) is experiencing a shift in volume toward cash pay, impacting revenues despite an increase in prescriptions filled. The company is halting its broadcast television promotion due to lower ROI, which may affect its market reach and brand awareness. Phathom Pharmaceuticals Inc (NASDAQ:PHAT) is deferring its phase 2 eosinophilic esophagitis study, which could impact its pediatric extension strategies. There is uncertainty regarding the FDA's decision on the company's citizen's petition, which is critical for its exclusivity timeline and could affect future market dynamics. Warning! GuruFocus has detected 5 Warning Signs with PHAT. Q: Can you provide more color on the timing of the C-suite changes and their impact on the CP process? What happens if the FDA needs more time for the CP decision? A: The management changes will not interrupt our CP activities. Our team, including OSI, will continue working with the FDA. If the FDA needs more time, we will likely need to take action to define our exclusivity period more formally, depending on the nature of our conversations with them. - Steve Bosta, President and CEO Q: Are you speaking to the same individuals at the FDA as before regarding the CP? How will the strategic reduction in DTC spending affect your target audience? A: There is some continuity in the FDA staff, but senior policy decisions are made by new administration members. Our sales activities are the key driver of growth, not the broad DTC initiatives, which provided a lower ROI. We are focusing on field sales to expand the prescriber base. - Steve Bosta, President and CEO Q: How should investors think about the impact of discontinuing DTC spend on script growth? What are your revenue expectations for 2025? A: We do not expect the changes to adversely impact our revenue ramp. The field sales activity is the core driver of revenue growth. We are comfortable with the current range of revenue projections for the year. - Steve Bosta, President and CEO Q: What are you seeing in the market dynamics currently, given the flat script growth in recent weeks? Any changes to gross-to-net expectations for 2025? A: Week-to-week variability is natural, and we remain comfortable with the range of analyst revenue estimates. Our gross-to-net discount rate was 53% in Q1, and we expect it to range between 55% and 65% for the year. - Steve Bosta, President and CEO; Mollie Henderson, Chief Financial and Business Officer Q: How many of the changes, like the pullback in DTC, were considered before you became CEO? What is your level of conviction on the CP response timing? Will pediatric studies continue? A: None of the changes were on the table before I joined. We expect the CP response in June, but FDA turnover could affect timing. We have paused the EOE study but will evaluate alternatives for pediatric extension. - Steve Bosta, President and CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
